X

Trial Profile

Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Japanese Subjects with Advanced Solid Malignant Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs U3 1565 (Primary)
Indications Solid tumours
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Daiichi Sankyo Company

Most Recent Events

10 Sep 2015 Dose expansion part is ongoing at dose level of 24 mg/kg weekly dose, according to the results presented at the 2013 European Cancer Congress.
10 Sep 2015 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI), JapicCTI-111484).
10 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com